Slide 1: Second Quarter 2026 Earnings Results: Prepared Remarks
SECOND QUARTER 2026 EARNINGS RESULTS Prepared Remarks, July 23, 2026 Conference operator: Welcome to the Quest Diagnostics Second Quarter 2026 conference call. At the request of the company, this call is being recorded. The entire contents of the call, including the presentation and question and ans
Slide 2: Second Quarter 2026 Earnings Results: Prepared Remarks
SECOND QUARTER 2026 EARNINGS RESULTS Prepared Remarks, July 23, 2026 Our strong performance in the second quarter demonstrates focused execution of our strategy to connect people and providers to innovative testing and actionable insights that illuminate paths for better health. In the quarter, we g
Slide 3: Second Quarter 2026 Earnings Results: Prepared Remarks
SECOND QUARTER 2026 EARNINGS RESULTS Prepared Remarks, July 23, 2026 portfolio, spanning risk assessment to post-transplant monitoring, for providers focused on this growing area of medicine. In the Hospital channel, we grew revenues at a double-digit rate during the quarter, primarily from Co-Lab S
Slide 4: Second Quarter 2026 Earnings Results: Prepared Remarks
SECOND QUARTER 2026 EARNINGS RESULTS Prepared Remarks, July 23, 2026 In oncology, we achieved key milestones for Haystack MRD® during the quarter. New York State approved the test, placing it among an elite group of solid tumor ctDNA MRD tests to fulfill the state’s rigorous quality criteria. This a
Slide 5: Second Quarter 2026 Earnings Results: Prepared Remarks
SECOND QUARTER 2026 EARNINGS RESULTS Prepared Remarks, July 23, 2026 Sam Samad: Thanks, Jim. In the second quarter, consolidated revenues were $3.04 billion, up 10.2% versus the prior year. Consolidated organic revenues grew by 10%. Revenues for Diagnostic Information Services were up 10.3% compared
Slide 6: Second Quarter 2026 Earnings Results: Prepared Remarks
SECOND QUARTER 2026 EARNINGS RESULTS Prepared Remarks, July 23, 2026 As previously indicated, adjusted EPS grew by 19.1% and, excluding the one-time tax benefit, grew by 15.3%. Cash from operations was $875 million year-to-date through the second quarter versus $858 million in the prior year. This y
Slide 7: Second Quarter 2026 Earnings Results: Prepared Remarks
SECOND QUARTER 2026 EARNINGS RESULTS Prepared Remarks, July 23, 2026 Jim Davis: Thanks, Sam. In summary, during the quarter: • We generated robust top- and bottom-line growth on focused execution of our strategy and sustained demand across physicians, hospitals and consumers. • Revenues increased by